Capital Wired

Keeps You Updated

Monday, January 18, 2021
Log in
  • Headlines
  • Business
  • Health
  • Tech & Science
  • Sports
  • World
  • US
  • Latest News
    • How To Make Your Own Home-Brewed Morphine
    • Using Mouthwash Too Often Puts You at Risk of Obesity and Diabetes
    • Walmart to Solve its Supply Chain Issues and Further Cut Down on Costs
    • The World’s Most Expensive Christmas Decorations
    • Netflix Hopes to Balance Data Limit With Great Video Quality
    • Joji Morishita says Japan Will Resume Whaling
    • The Most Beloved Plastic Surgeries Among Americans
    • Skype for Web Allows Non-Users to Take Part In Its Online Chats

Pages

  • About Capital Wired
  • Contact Us
  • Privacy Policy GDPR
  • Reprint & Licensing
  • Staff
  • Terms of Use

Recent Posts

  • Here’s Why Your Brain Keeps Worrying about Everything June 29, 2018
  • Don’t Throw That Sunscreen after Summer Is Up June 29, 2018
  • Analysts: Currency War between U.S. and China Might Be Looming June 28, 2018
  • Starbucks Rival The Coffee Bean & Tea Leaf Opening 100 Shops June 27, 2018
  • Study Finds We Are Alone in the Universe June 26, 2018
  • Restaurant Owner Not Sorry for Booting Sarah Sanders June 26, 2018
  • Beware of the Hidden Salt in Your Food! June 25, 2018

Bayer Partners With CRISPR For Easier Gene Editing

December 23, 2015 By Chen Lai Leave a Comment

Email, RSS Follow
"human dna"

Our double-helix DNA has been a constant source of questions and answers since it was first discovered in 1953.

In order to combat the steady rise in genetic disease prevalence, Bayer partners with CRISPR for easier gene editing technology research and development. By merging CRISPR’s Cas-9 technology with Bayer’s protein engineering techniques and general knowledge in regards to diseases, the discovery of a process of developing viable commercial gene-editing methods will be done at a much faster rate.

This allegiance is the first of its kind in regards to its long term applicability. Bayer will fund the research part with over $300 million in investments while at the same time, gaining a minority stake in CRISPR’s shares equivalent to $35 million. Through the use of these funds, the joint venture will have the task of coming up with a viable delivery system for Cas-9’s gene editing potential towards live human patients.

The aforementioned Cas-9 has been already used to modify genes in a type of filamentous fungus used in the Japanese industry. The fungus Aspergillus oryzae is used in the production of soy sauce and sake. The editing process consists of introducing plasmids carrying the Cas-9 protein which guide the RNA into producing gene mutations inside the fungus’ system. The mutagenesis produced had an efficiency increase ranging from 10% to 20%. Other fungi pertaining to the same filamentous type have benefited from gene editing as well, gaining the same boost in mutation efficiency.

The Bayer company will gain 50% of the profits gathered from the commercialization of an eventual gene-editing therapy towards humans from the targeted areas. These areas consist of genetic illnesses that lead to blindness, blood disease and congenital heart disease. The findings achieved through this joint venture will be split into two parts.

CRISPR will be focused on developing therapies aimed at human patients suffering from the aforementioned diseases. On the other hand, Bayer will have its focus aimed towards the development of therapies for agricultural-based products and other non-human applicants. Even if they have two different areas of the gene-editing spectrum, both parent companies will have undisclosed access to any findings achieved by their joint venture.

The CEO position of the newly formed partnership will be held by the current Head of BLSC, Dr. Axel Bouchon, on an interim basis. The interim board Chairman will be the co-founder and CEO of CRISPR Therapeutics, Dr. Roger Novak. The partnership will remain active for at least the next five years, with funding from Bayer being constantly added until 2020.

Taking into account the recent news stating that Bayer partners up with CRISPR for easier gene editing techniques research and development, this area of medical science will benefit from a massive boost in the coming years. The Cas-9 gene therapy has already been regarded as an important scientific discovery, but its applicability in human patients cannot be addressed given our current technological level. Hopefully, this will change as more and more scientific breakthroughs are made around the globe with each passing week, ranging from new links between diseases and genes to the cure for diabetes patients.

Image source:www.pixabay.com

Email, RSS Follow

Chen Lai

Chen Lai

With over 6 years of experience in writing news about various topics, able and efficient to write news related to the health, business and technology market. Chen Lai can be reached at [email protected]

Filed Under: Tech & Science Tagged With: Bayer Partners With CRISPR For Easier Gene Editing, Cas-9 protein, minority stake, parent companies, proteic plasmids, RNA mutation, sake fungus, soy sauce

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Recent Articles

dc logo on black galaxy background

Ava DuVernay to Direct DC’s New Gods Adaptation

March 16, 2018 By Rebecca McGhee Leave a Comment

leonardo davinci's signature in black

Is DaVinci’s Record Breaking Painting Authentic?

November 20, 2017 By Rebecca McGhee Leave a Comment

stephen hawking

Stephen Hawking Makes Gloomy Prediction For Earth In A 100 Years

May 7, 2017 By Deborah Nielsen Leave a Comment

"Dwayne Johnson not dead"

Dwayne Johnson Died this Week or Not

January 19, 2016 By Jason Leathers 3 Comments

There Are At Least Three More Seasons of Game of Thrones To Go

July 31, 2015 By Rebecca McGhee Leave a Comment

Homelessness Soars in L.A., Officials Pledge to House Everybody by 2016

May 12, 2015 By Brian Galloway Leave a Comment

FBI Releases National Report on Slain Police Officers, Figures are Alarming

May 12, 2015 By Rebecca McGhee Leave a Comment

New York Nuclear Plant Partially Shut Down due to Hudson Oil Slick

May 11, 2015 By Jason Leathers 2 Comments

Obama Draws Heat from Democrats over Asia Trade Deal

May 9, 2015 By Rebecca McGhee Leave a Comment

Florida Governor Changes Stance on Obamacare Once More, Budget on Hold

May 9, 2015 By Brian Galloway Leave a Comment

Secret Service to add an Extra Layer of Spikes to White House Fence

May 8, 2015 By Chen Lai Leave a Comment

Police Arrested Suspect in death of Student who tried to Sell Car on Craigslist

May 8, 2015 By Deborah Nielsen 1 Comment

AccuWeather.com: 2015 Atlantic Tropical Storm Season is Officially Open

May 7, 2015 By Deborah Nielsen Leave a Comment

Illinois Student Found Dead after Trying to Sell his Car on Craigslist

May 7, 2015 By Deborah Nielsen 2 Comments

Related Articles

  • ET movie

    Study Finds We Are Alone in the Universe

    Jun 26, 2018
  • Sarah Huckabee Sanders

    Restaurant Owner Not Sorry for Booting Sarah Sanders

    Jun 26, 2018
  • New Type of Photosynthesis Spotted in Blue-Green Algae

    Jun 20, 2018
  • Tropical fish and coral reef

    Coral Reefs Save Us from Flooding (Study)

    Jun 14, 2018
  • NASA astronaut on the moon

    NASA Astronauts Warmed Up the Moon in the 1970s

    Jun 12, 2018
  • Antarctic landscape

    Antarctica Experiencing Routine Earthquakes Like Any Other Continent

    Jun 5, 2018
  • SpaceX Falcon 9 rocket launch

    SpaceX Launches Powerful Communications Satellite into Orbit

    Jun 5, 2018
  • Planet Pluto

    Scientists Have New Theory About Pluto’s Formation

    May 30, 2018
  • The Milky Way

    NASA Uses Lasers to Re-Create Coldest Spot in the Universe

    May 22, 2018
  • Plastic bottle on a sand beach

    Earth Has Had 33 Years of Above-than-Average Temperatures

    May 21, 2018

Categories

  • Business
  • Headlines
  • Health
  • Sports
  • Tech & Science
  • US
  • World

Copyright © 2021 capitalwired.com

About · Privacy Policy · Terms of Use · Contact

This website uses cookies to ensure you get the best experience on our website. Learn more.